"Lash serum without prostaglandin" is searched about 2,300 times a month in the US, and the phrasings around it — prostaglandin lash serum, isopropyl cloprostenate, peptide lash serum — bring the pool to about 4,650 (clickstream estimate, October 2026). The question behind them is practical: which lash serums contain the drug-like ingredient, and does it matter? This page answers it from what can be checked as of 11 October 2026: what each kind of serum contains, how to read the label, what Europe's safety committee concluded this year, and what has been reported. It is not a recommendation for any product.
Two kinds of lash serum
| Prostaglandin-analogue serum | Peptide serum | |
|---|---|---|
| Active idea | a synthetic analogue of prostaglandin F2α, the drug class used to lower eye pressure in glaucoma | short peptides, most often myristoyl pentapeptide-17, sometimes with biotin, panthenol or plant extracts |
| Why it is used | lash growth was a recognised side effect of glaucoma drugs before it became a product | promoted as conditioning or "lash-supporting" |
| Evidence for lash growth | strong for bimatoprost, the licensed drug; little published for the cosmetic analogues | no indexed study of myristoyl pentapeptide-17 |
| Known side effects | eye itching and redness, eyelid darkening, periorbital fat loss reported with the class | none documented in the indexed literature |
| Regulatory position | prescription drug in LATISSE; sold as a cosmetic ingredient elsewhere | cosmetic |
A 2026 survey of 79 lash-lengthening cosmetics found that about 30% contained a prostaglandin analogue; that survey, and the peptide's own evidence file, are on our page for myristoyl pentapeptide-17, so they are not restated here.
How to spot the analogue on a label
The analogues have distinctive INCI names. Any of these in the full ingredient list means the serum is a prostaglandin product, whatever the front of the box says:
- isopropyl cloprostenate (IPCP)
- ethyl tafluprostamide
- dechloro dihydroxy difluoro ethylcloprostenolamide (DDDE)
- methylamido dihydro noralfaprostal (MDN)
- bimatoprost and norbimatoprost
Free amino acids — alanine, arginine, glycine, proline — and hydrolysed proteins are not peptides in the sense the marketing implies, and a word like "peptide-packed" next to a plant ferment is not a declared peptide either.
A worked example, with no verdict on the product. GrandeLASH-MD's US product page, read on 11 October 2026 (price shown $68), describes the serum as "infused with a blend of vitamins, peptides, and amino acids". Its declared ingredient list carries no peptide INCI name: it lists a radish root ferment, a run of free amino acids and isopropyl cloprostenate (an analog of prostaglandin), and the page states that the product "contains (a small amount of) isopropyl cloprostenate". The analogue is disclosed; the peptide is not on the list. That pattern — peptides in the copy, a prostaglandin analogue in the list — is the reason to read the list. By contrast, the peptide-only serum covered in our analysis of The Ordinary's lash and brow serum declares no analogue.
What Europe's safety committee concluded in 2026
The EU's Scientific Committee on Consumer Safety assessed four analogues used in lash and brow products after industry submitted new data: ethyl tafluprostamide (up to 0.018%), MDN (up to 0.03%), isopropyl cloprostenate (up to 0.005%) and DDDE. Its opinion, SCCS/1680/25, preliminary on 28 May 2025, was adopted on 2 February 2026 and published on 10 February 2026. Its conclusion: "none of them can be considered safe for use in cosmetic products intended for promoting the growth of eyelashes and eyebrows", because of the analogues' "potent pharmacological activity … even at low concentrations" and a lack of acceptable data to exclude reproductive and developmental toxicity.
Two cautions on reading it. It is a scientific opinion to the European Commission, which decides whether to restrict or ban a substance; we found no amendment to the EU cosmetics regulation enacted on it as of 11 October 2026. And it concerns cosmetic use: bimatoprost as a licensed medicine is regulated separately.
The licensed product, for comparison
In the US, the one lash-growth product FDA has approved is LATISSE (bimatoprost ophthalmic solution 0.03%, NDA 022369, approved 24 December 2008), a prescription drug for hypotrichosis — too few or too short lashes. Its current label (July 2024) lists the most common adverse reactions as eye itching, conjunctival redness and skin darkening at about 3–4%, and warns that eyelid and iris pigmentation may occur, the iris change "likely to be permanent", along with hair growth outside the treated area and an effect on eye pressure in people using glaucoma drops. A cosmetic analogue serum goes through no comparable review before sale: in the US, cosmetics do not need FDA approval.
What has been reported with cosmetic analogue serums
The published record is small and made of case reports and photographs, not trials. A PubMed search on 11 October 2026 returned 4 records naming isopropyl cloprostenate and 1 naming ethyl tafluprostamide. The relevant ones:
- A woman of 32 developed discoloration around the eyes while using an isopropyl cloprostenate serum, fading after she stopped (Horváth 2017).
- A woman of 35 developed thin, darker skin and hollowing around the eyes after ten months of an isopropyl cloprostenate serum, reversing six months after stopping. The same paper had blinded graders compare manufacturers' own before-and-after photographs: analogue serums drew a mean grade of 8.2 of 19 for signs of periorbital fat loss, against 2.3 for non-analogue serums and 3.2 for false lashes. The authors add that the customer-facing ingredient list "often" did not mention the analogue (Jamison 2022).
- A 2024 review of eyelash serums found the strongest evidence for bimatoprost and judged that both other analogues and non-prostaglandin ingredients need further study (Baiyasi 2024).
Periorbital fat loss, known in glaucoma care as prostaglandin-associated periorbitopathy, is a documented effect of the drug class at eye-drop doses. Whether cosmetic concentrations cause it at a measurable rate is not established by any trial; the evidence is two case reports and a photograph study.
What is and is not established
Established: prostaglandin analogues are the ingredient class with a known effect on lash growth, through the licensed drug bimatoprost; about 30% of surveyed lash cosmetics contain one; the analogues have recognisable INCI names; the EU's safety committee concluded in February 2026 that none of four analogues assessed can be considered safe in lash and brow cosmetics; case reports describe periocular darkening and volume loss that faded after stopping.
Not established: how often cosmetic analogue serums cause side effects, since no trial has measured it; whether peptide-only serums lengthen lashes at all; and whether the EU opinion will become law. Anyone noticing eye irritation, eyelid darkening or hollowing, or who uses glaucoma medication, should raise it with an eye doctor. The same evidence test applied to scalp hair is in our hair growth hub.
Sources
- Scientific Committee on Consumer Safety. Opinion on prostaglandin analogues: Ethyl Tafluprostamide, Methylamido-Dihydro-Noralfaprostal (MDN), Isopropyl Cloprostenate (IPCP) and DDDE, SCCS/1680/25; preliminary 2025-05-28, final adopted 2026-02-02, published 2026-02-10. European Commission, health.ec.europa.eu, read 2026-10-11.
- LATISSE (bimatoprost ophthalmic solution) 0.03%: Drugs@FDA NDA 022369 (AbbVie; original approval 2008-12-24) and prescribing information effective 2024-07-01 (Indications, Adverse Reactions, Warnings and Precautions), via openFDA, read 2026-10-11.
- Grande Cosmetics, GrandeLASH-MD product page, grandecosmetics.com/products/grandelash-md (ingredient list, product copy, warning text, price), read 2026-10-11.
- Jamison A, Okafor L, Ullrich K, Schiedler V, Malhotra R. Do prostaglandin analogue lash lengtheners cause eyelid fat and volume loss? Aesthet Surg J 2022;42(11):1241-9. PMID 35700523.
- Horváth ON, Letulé V, Ruzicka T, et al. Periocular discoloration after using a prostaglandin analog for eyelash enhancement: evaluation with reflectance confocal microscopy. J Cosmet Dermatol 2017;16(1):18-20. PMID 27595988.
- Baiyasi M, St Claire K, Hengy M, et al. Eyelash serums: a comprehensive review. J Cosmet Dermatol 2024;23(7):2328-44. PMID 38475901.
- Couteau C, Coiffard L. Prostaglandin analogues in cosmetic products formulated for eyelash lengthening. Ann Pharm Fr 2026;84(5):889-98. PMID 42269767.
- PubMed E-utilities searches, 2026-10-11:
cloprostenate[tiab](4);tafluprostamide[tiab](1);(eyelash*[tiab] OR lash[tiab]) AND (serum*[tiab] OR cosmetic*[tiab]) AND (prostaglandin*[tiab] OR bimatoprost[tiab] OR cloprostenol*[tiab] OR tafluprost*[tiab]) AND (adverse[tiab] OR periorbitopathy[tiab] OR "case report"[pt] OR complication*[tiab])(12, titles read).